D-0832-2020 Class II Terminated

Recalled by Graviti Pharmaceuticals Private Limited — Medak, N/A

FDA drug recall D-0832-2020 was initiated by Graviti Pharmaceuticals Private Limited on Jan 28, 2020 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules: Customer complaint that one 20 mg Atorvastatin Calcium Tablet was present in a bottle labeled as and containing eight-nine Atorvastatin Calcium Tablets, USP 10… The recall status is terminated (terminated Nov 29, 2022). Affected quantity: 29,056 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 12, 2020
Initiation Date
Jan 28, 2020
Termination Date
Nov 29, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
29,056 bottles

Product description

Atorvastatin Calcium Tablets, USP, 10 mg*, 90-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ 08830-3009 USA; Manufactured By: Graviti Pharmaceuticals Pvt. Ltd., Telangana -502307, INDIA; NDC 70377-027-11.

Reason for recall

Presence of Foreign Tablets/Capsules: Customer complaint that one 20 mg Atorvastatin Calcium Tablet was present in a bottle labeled as and containing eight-nine Atorvastatin Calcium Tablets, USP 10 mg.

Distribution pattern

Nationwide in the USA.

Code information

Lot #: ATA318099C, Exp 12/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0832-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0832-2020. Report a data issue: hello@regdatalab.com.